These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16128265)

  • 21. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.
    Boyaka PN; Tafaro A; Fischer R; Fujihashi K; Jirillo E; McGhee JR
    Curr Pharm Des; 2003; 9(24):1965-72. PubMed ID: 12871182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    FEMS Immunol Med Microbiol; 2002 Feb; 32(3):179-85. PubMed ID: 11934561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal immunisation: adjuvants and delivery systems.
    Moyle PM; McGeary RP; Blanchfield JT; Toth I
    Curr Drug Deliv; 2004 Oct; 1(4):385-96. PubMed ID: 16305400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E; Verdonck F; Vanrompay D; Goddeeris B
    Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
    Sugai T; Mori M; Nakazawa M; Ichino M; Naruto T; Kobayashi N; Kobayashi Y; Minami M; Yokota S
    Vaccine; 2005 Nov; 23(46-47):5450-6. PubMed ID: 16006019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases.
    Marciani DJ
    Autoimmunity; 2017 Nov; 50(7):393-402. PubMed ID: 28906131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulating vaccine responses with dendritic cells and Toll-like receptors.
    Pulendran B
    Immunol Rev; 2004 Jun; 199():227-50. PubMed ID: 15233738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in mucosal vaccine development.
    Chen H
    J Control Release; 2000 Jul; 67(2-3):117-28. PubMed ID: 10825547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal adjuvants.
    Harandi AM; Medaglini D
    Curr HIV Res; 2010 Jun; 8(4):330-5. PubMed ID: 20353395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium phosphate nanoparticles as a new generation vaccine adjuvant.
    Lin Y; Wang X; Huang X; Zhang J; Xia N; Zhao Q
    Expert Rev Vaccines; 2017 Sep; 16(9):895-906. PubMed ID: 28712326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of improved mucosal vaccines by induction of innate immunity.
    Lavelle EC
    Cell Mol Life Sci; 2005 Dec; 62(23):2750-70. PubMed ID: 16237500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice.
    Yu S; Tang C; Shi X; Yang P; Xing L; Wang X
    Vaccine; 2012 Aug; 30(36):5425-36. PubMed ID: 22709954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal adjuvants.
    Stevceva L; Ferrari MG
    Curr Pharm Des; 2005; 11(6):801-11. PubMed ID: 15777234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Strategies for mucosal vaccine development.
    Boyaka PN; Marinaro M; Vancott JL; Takahashi I; Fujihashi K; Yamamoto M; van Ginkel FW; Jackson RJ; Kiyono H; McGhee JR
    Am J Trop Med Hyg; 1999 Apr; 60(4 Suppl):35-45. PubMed ID: 10344675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.